EFFECT OF COMBINED THERAPY WITH CARVEDILOL AND SAROGLITAZAR ON HEPATIC FIBROSIS IN PATIENTS WITH MASLD

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20260405010

Enrollment

200

Registered

2026-04-05

Start date

2026-03-05

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MASLD Hepatic Fibrosis Hypertension Dyslipidemia Diabetes MASLD NAFLD HTN DM

Interventions

Patients with MASLD

Supportive Care

Carvedilol Saroglitazar combination therapy patients

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1.Male and female adults (Aged between 18 years to 100 years) included in the study 2.Determined to satisfy the criteria for MASLD 3. Patients with Hypertension 4. Patients with Diabetes 5. Patients with Dyslipidemia

Exclusion criteria

Exclusion criteria: 1. Patients with Chronic viral hepatitis

Design outcomes

Primary

Measure	Time frame
Hepatic Fibrosis three and six months Fibroscan	—

Secondary

Measure	Time frame
Liver function test three and six months Serum LFT	—

Countries

India

Contacts

Public ContactIndrajit Suresh

CEG Hospital

indrajit.suresh@gmail.com8197115522

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026